Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Pharmacokinetics and Biodistribution of a [89Zr]Zr-DFO-MSTP2109A Anti-STEAP1 Antibody in Metastatic Castration-Resistant Prostate Cancer Patients.

O'Donoghue JA, Danila DC, Pandit-Taskar N, Beylergil V, Cheal SM, Fleming SE, Fox JJ, Ruan S, Zanzonico PB, Ragupathi G, Lyashchenko SK, Williams SP, Scher HI, Fine BM, Humm JL, Larson SM, Morris MJ, Carrasquillo JA.

Mol Pharm. 2019 Jul 1;16(7):3083-3090. doi: 10.1021/acs.molpharmaceut.9b00326. Epub 2019 May 31.

PMID:
31117485
2.

Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using 89Zr-DFO-MSTP2109A Anti-STEAP1 Antibody.

Carrasquillo JA, Fine BM, Pandit-Taskar N, Larson SM, Fleming SE, Fox JJ, Cheal SM, O'Donoghue JA, Ruan S, Ragupathi G, Lyashchenko SK, Humm JL, Scher HI, Gönen M, Williams SP, Danila DC, Morris MJ.

J Nucl Med. 2019 Nov;60(11):1517-1523. doi: 10.2967/jnumed.118.222844. Epub 2019 May 3.

PMID:
31053681
3.

A Phase I Study of Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission.

O'Cearbhaill RE, Ragupathi G, Zhu J, Wan Q, Mironov S, Yang G, Spassova MK, Iasonos A, Kravetz S, Ouerfelli O, Spriggs DR, Danishefsky SJ, Sabbatini PJ.

Cancers (Basel). 2016 Apr 22;8(4). pii: E46. doi: 10.3390/cancers8040046.

4.

Quillaja Saponin Variants with Central Glycosidic Linkage Modifications Exhibit Distinct Conformations and Adjuvant Activities.

Walkowicz WE, Fernández-Tejada A, George C, Corzana F, Jiménez-Barbero J, Ragupathi G, Tan DS, Gin DY.

Chem Sci. 2016 Mar;7(3):2371-2380. Epub 2016 Jan 15.

5.

Correction: Mitochondrial Ceramide-Rich Macrodomains Functionalize Bax upon Irradiation.

Lee H, Rotolo JA, Mesicek J, Penate-Medina T, Rimner A, Liao WC, Yin X, Ragupathi G, Ehleiter D, Gulbins E, Zhai D, Reed JC, Haimovitz-Friedman A, Fuks Z, Kolesnick R.

PLoS One. 2015 Dec 30;10(12):e0146210. doi: 10.1371/journal.pone.0146210. eCollection 2015. No abstract available.

6.

Molecular basis of antibody binding to mucin glycopeptides in lung cancer.

Qu J, Yu H, Li F, Zhang C, Trad A, Brooks C, Zhang B, Gong T, Guo Z, Li Y, Ragupathi G, Lou Y, Hwu P, Huang W, Zhou D.

Int J Oncol. 2016 Feb;48(2):587-94. doi: 10.3892/ijo.2015.3302. Epub 2015 Dec 18.

7.

HLA-DR peptide occupancy can be regulated with a wide variety of small molecules.

Blazekovic F, Odukoya D, Butler SN, Mauro JA, Ramsamooj M, Puleo E, Szekeres K, Dana D, Kumar S, Ragupathi G, Blanck G.

Hum Vaccin Immunother. 2016 Mar 3;12(3):593-8. doi: 10.1080/21645515.2015.1089370.

8.

Design, synthesis, and immunologic evaluation of vaccine adjuvant conjugates based on QS-21 and tucaresol.

Fernández-Tejada A, Chea EK, George C, Gardner JR, Livingston PO, Ragupathi G, Tan DS, Gin DY.

Bioorg Med Chem. 2014 Nov 1;22(21):5917-23. doi: 10.1016/j.bmc.2014.09.016. Epub 2014 Sep 17.

9.

Development of a minimal saponin vaccine adjuvant based on QS-21.

Fernández-Tejada A, Chea EK, George C, Pillarsetty N, Gardner JR, Livingston PO, Ragupathi G, Lewis JS, Tan DS, Gin DY.

Nat Chem. 2014 Jul;6(7):635-43. doi: 10.1038/nchem.1963. Epub 2014 Jun 1.

10.

Phase I trial of a bivalent gangliosides vaccine in combination with β-glucan for high-risk neuroblastoma in second or later remission.

Kushner BH, Cheung IY, Modak S, Kramer K, Ragupathi G, Cheung NK.

Clin Cancer Res. 2014 Mar 1;20(5):1375-82. doi: 10.1158/1078-0432.CCR-13-1012. Epub 2014 Feb 11.

11.

Applying PET to broaden the diagnostic utility of the clinically validated CA19.9 serum biomarker for oncology.

Viola-Villegas NT, Rice SL, Carlin S, Wu X, Evans MJ, Sevak KK, Drobjnak M, Ragupathi G, Sawada R, Scholz WW, Livingston PO, Lewis JS.

J Nucl Med. 2013 Nov;54(11):1876-82. doi: 10.2967/jnumed.113.119867. Epub 2013 Sep 12.

12.

Accelerated tumor growth mediated by sublytic levels of antibody-induced complement activation is associated with activation of the PI3K/AKT survival pathway.

Wu X, Ragupathi G, Panageas K, Hong F, Livingston PO.

Clin Cancer Res. 2013 Sep 1;19(17):4728-39. doi: 10.1158/1078-0432.CCR-13-0088. Epub 2013 Jul 5.

13.

Synthesis and preclinical evaluation of QS-21 variants leading to simplified vaccine adjuvants and mechanistic probes.

Chea EK, Fernández-Tejada A, Damani P, Adams MM, Gardner JR, Livingston PO, Ragupathi G, Gin DY.

J Am Chem Soc. 2012 Aug 15;134(32):13448-57. doi: 10.1021/ja305121q. Epub 2012 Aug 6.

14.

Deciphering structural elements of mucin glycoprotein recognition.

Borgert A, Heimburg-Molinaro J, Song X, Lasanajak Y, Ju T, Liu M, Thompson P, Ragupathi G, Barany G, Smith DF, Cummings RD, Live D.

ACS Chem Biol. 2012 Jun 15;7(6):1031-9. doi: 10.1021/cb300076s. Epub 2012 Apr 9.

15.

Immunization with N-propionyl polysialic acid-KLH conjugate in patients with small cell lung cancer is safe and induces IgM antibodies reactive with SCLC cells and bactericidal against group B meningococci.

Krug LM, Ragupathi G, Hood C, George C, Hong F, Shen R, Abrey L, Jennings HJ, Kris MG, Livingston PO.

Cancer Immunol Immunother. 2012 Jan;61(1):9-18. doi: 10.1007/s00262-011-1083-6. Epub 2011 Aug 3.

16.

Mitochondrial ceramide-rich macrodomains functionalize Bax upon irradiation.

Lee H, Rotolo JA, Mesicek J, Penate-Medina T, Rimner A, Liao WC, Yin X, Ragupathi G, Ehleiter D, Gulbins E, Zhai D, Reed JC, Haimovitz-Friedman A, Fuks Z, Kolesnick R.

PLoS One. 2011;6(6):e19783. doi: 10.1371/journal.pone.0019783. Epub 2011 Jun 13. Erratum in: PLoS One. 2015;10(12):e0146210.

17.

Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer.

Ragupathi G, Gardner JR, Livingston PO, Gin DY.

Expert Rev Vaccines. 2011 Apr;10(4):463-70. doi: 10.1586/erv.11.18. Review.

18.

Human monoclonal antibodies to sialyl-Lewis (CA19.9) with potent CDC, ADCC, and antitumor activity.

Sawada R, Sun SM, Wu X, Hong F, Ragupathi G, Livingston PO, Scholz WW.

Clin Cancer Res. 2011 Mar 1;17(5):1024-32. doi: 10.1158/1078-0432.CCR-10-2640. Epub 2011 Feb 22.

19.

Impact of minimal tumor burden on antibody response to vaccination.

Kim SK, Wu X, Ragupathi G, Gathuru J, Koide F, Cheung NK, Panageas K, Livingston PO.

Cancer Immunol Immunother. 2011 May;60(5):621-7. doi: 10.1007/s00262-011-0975-9. Epub 2011 Jan 26.

20.

The known immunologically active components of Astragalus account for only a small proportion of the immunological adjuvant activity when combined with conjugate vaccines.

Hong F, Xiao W, Ragupathi G, Lau CB, Leung PC, Yeung KS, George C, Cassileth B, Kennelly E, Livingston PO.

Planta Med. 2011 May;77(8):817-24. doi: 10.1055/s-0030-1250574. Epub 2010 Dec 2.

21.

Preclinical evaluation of the synthetic adjuvant SQS-21 and its constituent isomeric saponins.

Ragupathi G, Damani P, Deng K, Adams MM, Hang J, George C, Livingston PO, Gin DY.

Vaccine. 2010 Jun 11;28(26):4260-7. doi: 10.1016/j.vaccine.2010.04.034. Epub 2010 May 5.

22.

Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes.

Wandall HH, Blixt O, Tarp MA, Pedersen JW, Bennett EP, Mandel U, Ragupathi G, Livingston PO, Hollingsworth MA, Taylor-Papadimitriou J, Burchell J, Clausen H.

Cancer Res. 2010 Feb 15;70(4):1306-13. doi: 10.1158/0008-5472.CAN-09-2893. Epub 2010 Feb 2.

23.

Design and synthesis of potent Quillaja saponin vaccine adjuvants.

Adams MM, Damani P, Perl NR, Won A, Hong F, Livingston PO, Ragupathi G, Gin DY.

J Am Chem Soc. 2010 Feb 17;132(6):1939-45. doi: 10.1021/ja9082842.

24.

From synthesis to biologics: preclinical data on a chemistry derived anticancer vaccine.

Zhu J, Wan Q, Lee D, Yang G, Spassova MK, Ouerfelli O, Ragupathi G, Damani P, Livingston PO, Danishefsky SJ.

J Am Chem Soc. 2009 Jul 8;131(26):9298-303. doi: 10.1021/ja901415s.

25.

Biologics through chemistry: total synthesis of a proposed dual-acting vaccine targeting ovarian cancer by orchestration of oligosaccharide and polypeptide domains.

Zhu J, Wan Q, Ragupathi G, George CM, Livingston PO, Danishefsky SJ.

J Am Chem Soc. 2009 Mar 25;131(11):4151-8. doi: 10.1021/ja810147j.

26.

Synthesis of sialyl Lewis(a) (sLe (a), CA19-9) and construction of an immunogenic sLe(a) vaccine.

Ragupathi G, Damani P, Srivastava G, Srivastava O, Sucheck SJ, Ichikawa Y, Livingston PO.

Cancer Immunol Immunother. 2009 Sep;58(9):1397-405. doi: 10.1007/s00262-008-0654-7. Epub 2009 Feb 4.

27.

Evaluation of widely consumed botanicals as immunological adjuvants.

Ragupathi G, Yeung KS, Leung PC, Lee M, Lau CB, Vickers A, Hood C, Deng G, Cheung NK, Cassileth B, Livingston P.

Vaccine. 2008 Sep 2;26(37):4860-5. doi: 10.1016/j.vaccine.2008.06.098. Epub 2008 Jul 18.

28.

Synthesis of QS-21-xylose: establishment of the immunopotentiating activity of synthetic QS-21 adjuvant with a melanoma vaccine.

Deng K, Adams MM, Damani P, Livingston PO, Ragupathi G, Gin DY.

Angew Chem Int Ed Engl. 2008;47(34):6395-8. doi: 10.1002/anie.200801885. No abstract available.

29.

Inflammation-associated lysophospholipids as ligands for CD1d-restricted T cells in human cancer.

Chang DH, Deng H, Matthews P, Krasovsky J, Ragupathi G, Spisek R, Mazumder A, Vesole DH, Jagannath S, Dhodapkar MV.

Blood. 2008 Aug 15;112(4):1308-16. doi: 10.1182/blood-2008-04-149831. Epub 2008 Jun 5.

30.

Fine specificity of natural killer T cells against GD3 ganglioside and identification of GM3 as an inhibitory natural killer T-cell ligand.

Park JE, Wu DY, Prendes M, Lu SX, Ragupathi G, Schrantz N, Chapman PB.

Immunology. 2008 Jan;123(1):145-55.

31.

Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer.

Sabbatini PJ, Ragupathi G, Hood C, Aghajanian CA, Juretzka M, Iasonos A, Hensley ML, Spassova MK, Ouerfelli O, Spriggs DR, Tew WP, Konner J, Clausen H, Abu Rustum N, Dansihefsky SJ, Livingston PO.

Clin Cancer Res. 2007 Jul 15;13(14):4170-7.

32.

A polyvalent vaccine for high-risk prostate patients: "are more antigens better?".

Slovin SF, Ragupathi G, Fernandez C, Diani M, Jefferson MP, Wilton A, Kelly WK, Morris M, Solit D, Clausen H, Livingston P, Scher HI.

Cancer Immunol Immunother. 2007 Dec;56(12):1921-30. Epub 2007 Jul 10.

PMID:
17619878
33.

Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21.

Gilewski TA, Ragupathi G, Dickler M, Powell S, Bhuta S, Panageas K, Koganty RR, Chin-Eng J, Hudis C, Norton L, Houghton AN, Livingston PO.

Clin Cancer Res. 2007 May 15;13(10):2977-85.

34.

Cancer vaccines targeting carbohydrate antigens.

Livingston PO, Ragupathi G.

Hum Vaccin. 2006 May-Jun;2(3):137-43. Epub 2006 May 16.

PMID:
17012906
35.

Preparation and evaluation of unimolecular pentavalent and hexavalent antigenic constructs targeting prostate and breast cancer: a synthetic route to anticancer vaccine candidates.

Ragupathi G, Koide F, Livingston PO, Cho YS, Endo A, Wan Q, Spassova MK, Keding SJ, Allen J, Ouerfelli O, Wilson RM, Danishefsky SJ.

J Am Chem Soc. 2006 Mar 1;128(8):2715-25.

PMID:
16492059
36.

Antibody inducing polyvalent cancer vaccines.

Ragupathi G, Gathuru J, Livingston P.

Cancer Treat Res. 2005;123:157-80. Review.

PMID:
16211870
37.

Carbohydrate vaccines as immunotherapy for cancer.

Slovin SF, Keding SJ, Ragupathi G.

Immunol Cell Biol. 2005 Aug;83(4):418-28. Review.

PMID:
16033538
38.

Identification of DHBcAg as a potent carrier protein comparable to KLH for augmenting MUC1 antigenicity.

Gathuru JK, Koide F, Ragupathi G, Adams JL, Kerns RT, Coleman TP, Livingston PO.

Vaccine. 2005 Sep 15;23(39):4727-33.

PMID:
15978705
39.

Selection of GM2, fucosyl GM1, globo H and polysialic acid as targets on small cell lung cancers for antibody mediated immunotherapy.

Livingston PO, Hood C, Krug LM, Warren N, Kris MG, Brezicka T, Ragupathi G.

Cancer Immunol Immunother. 2005 Oct;54(10):1018-25. Epub 2005 May 31.

PMID:
15926079
40.

Synthesis of selected LeY and KH-1 analogues: a medicinal chemistry approach to vaccine optimization.

Spassova MK, Bornmann WG, Ragupathi G, Sukenick G, Livingston PO, Danishefsky SJ.

J Org Chem. 2005 Apr 29;70(9):3383-95.

PMID:
15844973
41.

Antibodies against tumor cell glycolipids and proteins, but not mucins, mediate complement-dependent cytotoxicity.

Ragupathi G, Liu NX, Musselli C, Powell S, Lloyd K, Livingston PO.

J Immunol. 2005 May 1;174(9):5706-12.

42.

A bivalent conjugate vaccine in the treatment of biochemically relapsed prostate cancer: a study of glycosylated MUC-2-KLH and Globo H-KLH conjugate vaccines given with the new semi-synthetic saponin immunological adjuvant GPI-0100 OR QS-21.

Slovin SF, Ragupathi G, Fernandez C, Jefferson MP, Diani M, Wilton AS, Powell S, Spassova M, Reis C, Clausen H, Danishefsky S, Livingston P, Scher HI.

Vaccine. 2005 May 2;23(24):3114-22.

PMID:
15837210
43.

Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer.

Slovin SF, Ragupathi G, Musselli C, Fernandez C, Diani M, Verbel D, Danishefsky S, Livingston P, Scher HI.

Cancer Immunol Immunother. 2005 Jul;54(7):694-702. Epub 2005 Feb 22.

PMID:
15726361
44.

Comparison of antigen constructs and carrier molecules for augmenting the immunogenicity of the monosaccharide epithelial cancer antigen Tn.

Kagan E, Ragupathi G, Yi SS, Reis CA, Gildersleeve J, Kahne D, Clausen H, Danishefsky SJ, Livingston PO.

Cancer Immunol Immunother. 2005 May;54(5):424-30. Epub 2004 Dec 30.

PMID:
15625606
45.

Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin.

Krug LM, Ragupathi G, Hood C, Kris MG, Miller VA, Allen JR, Keding SJ, Danishefsky SJ, Gomez J, Tyson L, Pizzo B, Baez V, Livingston PO.

Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6094-100.

46.

Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside.

Chapman PB, Wu D, Ragupathi G, Lu S, Williams L, Hwu WJ, Johnson D, Livingston PO.

Clin Cancer Res. 2004 Jul 15;10(14):4717-23.

47.

Vaccination of small cell lung cancer patients with polysialic acid or N-propionylated polysialic acid conjugated to keyhole limpet hemocyanin.

Krug LM, Ragupathi G, Ng KK, Hood C, Jennings HJ, Guo Z, Kris MG, Miller V, Pizzo B, Tyson L, Baez V, Livingston PO.

Clin Cancer Res. 2004 Feb 1;10(3):916-23.

48.

Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine.

Slovin SF, Ragupathi G, Musselli C, Olkiewicz K, Verbel D, Kuduk SD, Schwarz JB, Sames D, Danishefsky S, Livingston PO, Scher HI.

J Clin Oncol. 2003 Dec 1;21(23):4292-8.

PMID:
14645418
49.

Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21.

Ragupathi G, Livingston PO, Hood C, Gathuru J, Krown SE, Chapman PB, Wolchok JD, Williams LJ, Oldfield RC, Hwu WJ.

Clin Cancer Res. 2003 Nov 1;9(14):5214-20.

50.

The case for polyvalent cancer vaccines that induce antibodies.

Ragupathi G, Livingston P.

Expert Rev Vaccines. 2002 Aug;1(2):193-206. Review.

PMID:
12901558

Supplemental Content

Loading ...
Support Center